Neurogene Inc.

Neurogene Inc. (NGNE) Market Cap

Neurogene Inc. has a market capitalization of $433.7M.

Financials based on reported quarter end 2025-12-31

Price: $27.85

โ–ฒ 2.22 (8.66%)

Market Cap: 433.74M

NASDAQ ยท time unavailable

CEO: Rachel L. McMinn

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2014-03-07

Website: https://www.neurogene.com

Neurogene Inc. (NGNE) - Company Information

Market Cap: 433.74M ยท Sector: Healthcare

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Analyst Sentiment

83%
Strong Buy

Based on 8 ratings

Analyst 1Y Forecast: $45.00

Average target (based on 2 sources)

Consensus Price Target

Low

$16

Median

$42

High

$46

Average

$36

Potential Upside: 30.2%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Headline metrics for the most recent quarter ended 2025-12-31: Revenue reported as 0, net income of -$24.7M, and EPS of -1.60. Net margin is therefore negative, and the company remains loss-making based on the latest figures provided. Free cash flow was also negative at about -$16.8M, with operating cash flow of approximately -$16.7M, while capital expenditures were modest at roughly -$0.1M. On the balance sheet, total assets were about $289.2M versus total liabilities of $24.3M, leaving equity of ~$264.9M. Net debt is reported as -$93.9M, indicating net cash rather than net borrowings. Shareholder returns have been supported by market momentum: the stock is up 32.65% over the past year and 22.98% over the last 6 months, with dividends and buybacks shown as none/absent in this dataset. Valuation specifics (P/E, FCF yield, ROE, and price-based multiples) are not provided, but the fixed analyst target (consensus $45) contrasts with the current price of $21.41. Overall, this profile points to continued operating cash burn despite strong cash positioning and meaningful positive share-price performance."

Revenue Growth

Neutral

Revenue is reported as 0 for the latest period, providing no measurable growth trend and indicating limited recognized topline activity in the dataset.

Profitability

Neutral

Net income is -$24.7M and EPS is -1.60, implying negative profitability and no evidence of margin expansion based on the latest figures.

Cash Flow Quality

Neutral

Free cash flow is negative at about -$16.8M, driven by negative operating cash flow. Capital expenditure is small, but the cash burn remains the key risk. Dividends are $0.

Leverage & Balance Sheet

Good

Balance sheet appears resilient: equity is ~$264.9M and net debt is -$93.9M (net cash). Liabilities are modest relative to assets, supporting near-term flexibility.

Shareholder Returns

Positive

Total shareholder return is strongly influenced by capital appreciation: shares are up 32.65% over 1 year and 22.98% over 6 months. Dividends are absent in the dataset, and buybacks are not provided.

Analyst Sentiment & Valuation

Fair

Analyst consensus target is $45 versus a current price of $21.41, implying upside in the stated target range. However, key valuation metrics (P/E, FCF yield) are not provided, and profitability is currently negative.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
๐Ÿ“

SEC Filings (NGNE)

ยฉ 2026 Stock Market Info โ€” Neurogene Inc. (NGNE) Financial Profile